曲美他嗪与低分子肝素治疗不稳定型心绞痛临床观察

Clinical Observation of Low Molecular Weight Heparin Combined with Trimetazidine on the Treatment of Unstable Angina Pectoris

目的：观察低分子肝素与曲美他嗪治疗不稳定型心绞痛（UAP）的疗效。方法：172例UAP患者随机分为2组,其中对照组88例;两组均常规给予硝酸酯类、β-受体阻滞剂及阿司匹林等;治疗给予低分子肝素钠4000 IU,2次/d,皮下注射,连用5～7d,加用曲美他嗪20mg,每日3次及心电图改变情况。结果：治疗组临床总有效率为90.91%,对照组总有效率为69.05%,治疗组明显优于对照组（P〈0.01）。治疗后治疗组ST段下降导联数（NST）ST段下降的数值总和（ΣST）及心肌缺血总负荷均较治疗前显著改善（P〈0.01）。治疗组有5例皮下瘀斑,2例进展为AMI;而对照组有8例进展为AMI。结论：低分子肝素联用曲美他嗪,治疗UAP安全有效。

Objective： To observe the effect of low molecular weight heparin combined with trimnetazidine on the treatment of unstable angina pectoris （UAP）. Method： Eightysix patients with UAP were divided into two groups. There were 84 patients in the treatment group and 88 patients in the control group. Allof them were given the nitroglycerin, beta - blockers and aspirinetc. Treatment group were used the low molecular weight heparin 4000IU, twice a day hypodermic, after five to seven days, added the trimetazidine 20 mg, three times a day ,it was used 15 days. The control group was used heparin sodium 5000IU,twice a day hypodermic,it was used five to seven days. Result： The total effective rate of the treatment group was 90.91% and the control group was 69.05%, the treatment group was much better than the control group （ P 〈 0.01 ）. The treatment group contained 5 cases of subcutaneous purpura, and only 2 patients witn AMI, but the control group has 8 patients with AMI . All the patients were treated with coronary interventional therapy. Conclusion： The low molecular weight heparin combined with trimteazidine is more safety and effectively on UAP.